TYK Medicines, Inc
17
5
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
Role: lead
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
Role: lead
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
Role: lead
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
Role: lead
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects
Role: lead
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
Role: lead
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects
Role: lead
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
Role: lead
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Role: lead
A Study of TYK-00540 in Adult Patients With Solid Tumors
Role: lead
A Study of TY-1091 in Patients With Advanced Solid Tumors
Role: lead
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Role: lead
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation
Role: lead
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
Role: lead
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Role: lead
A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers
Role: lead
A Study of TY-302 in Patients With Advanced Solid Tumors
Role: lead
All 17 trials loaded